Phase II Study on EANI Combined with Hydrochloride Palonosetron for Prevention of Chemotherapy-induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy

Objective: To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloridepalonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenicchemotherapy.
Methods: Patients who received highly emetogenic chemotherapy were randomly assigned toa treatment group (60 patients) treated with EANI combined with hydrochloride palonosetron, and controlgroup (also 60 patients) given only hydrochloride palonosetron. Chemotherapy related nausea and vomitingwere observed and recorded in both groups of patients from the start till the end of chemotherapy.
Results:Complete control rates of vomiting in treatment and control group were 40%, and 35%, respectively, withoutany statistical ly significant difference (p> 0.05); however the response rates are 95.0%, 78.3%, respectively, withstatistical difference (p< 0.05). Complete control rates of nausea in treatment and control group were 36.7%,30%, respectively, without statistical difference (p> 0.05); but the response rates are 90.0%, 76.7%, respectively,with statistical difference (p<0.05).
Conclusion: EANI combined with hydrochloride palonosetron for preventionof nausea and vomiting induced by chemotherapy could be more effective than hydrochloride palonosetron alone,and can be recommended for use in prevention and treatment of chemotherapy-induced nausea and vomitingfollowing highly emetogenic chemotherapy.